Obicetrapib not checked

NewAmsterdam Pharma · 10 mg tablet · TA-8995

FollowEvery change as it happens, and a Monday email
Next date
Phase 3 trial completes
Trials
7 active
19 in total · 4 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“10 mg obicetrapib for 8 weeks followed by 10 mg obicetrapib/ 140 mg evolocumab (every 2 weeks) combination for 8 weeks”In the company’s words, NCT06496243 on ClinicalTrials.gov
Tested for
Lipidemia (2 trials), Atherosclerotic Cardiovascular Disease, Mixed Dyslipidemia, Hypercholesterolaemia, Coronary Artery Disease, Plaque, Atherosclerotic, Type 2 Diabetes (T2DM), Metabolic Syndrome (MetS) and 3 more
Main trialPhase 3
“This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD) who are not adequately controlled despite maximally tolerated lipid-lowering therapy.”In the company’s words, NCT05202509 on ClinicalTrials.gov
Other names
tablets · FDC · 10 mg tablet · CETP inhibitor · Repatha · TA-8995

Other drugs for Atherosclerotic Cardiovascular Disease

All 29 drugs for Atherosclerotic Cardiovascular Disease

Coming up6

Changes1

Last 90 days

Trials19

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting Nov 2026 Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease
Phase 3Recruiting Jan 2027 Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days
Phase 3Active, not recruiting Nov 2027 A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque
Phase 3Active, not recruiting Mar 2028 A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
Phase 2Recruiting Sep 2026 Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers
Phase 2Recruiting Nov 2026 Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels
Phase 2Recruiting Sep 2028 Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease
Phase 3Completed 28 May 2024 Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.
Phase 3Completed 26 Sep 2024 Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies
Phase 2Completed 7 May 2021 Randomized Study of Obicetrapib in Combination With Ezetimibe
Phase 2Completed 24 May 2021 Randomized Study of Obicetrapib as an Adjunct to Statin Therapy
Phase 2Completed 12 Aug 2022 Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy
Phase 2Completed 24 Mar 2023 A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy.
Phase 2Completed 9 May 2023 Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease
Phase 1Completed 2 Dec 2023 A Drug-drug Interaction Study Evaluating the PK Effects of Obicetrapib on Atorvastatin and Rosuvastatin
Phase 1Completed 12 Mar 2024 PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function
Phase 1Completed 25 Apr 2024 Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib
Phase 1Unknown 26 Sep 2024 Investigating the Effect of Obicetrapib on Lipoprotein Metabolism
Phase 1Completed 12 Nov 2024 A Study to Evaluate Drug-Drug Interactions of Obicetrapib Tablets and Ezetimibe Tablets in Healthy Adult Subjects
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Obicetrapib

Following is part of Solo: you see every change to Obicetrapib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in